-
Electronic (PDF - 1 Year Sub.)
-
Electronic (Online Access)
-
Enterprisewide
-
Enterprisewide
The Pharmaceutical Market: Slovenia
Espicom Business Intelligence Ltd, May 2012, Pages: 56
These highly regarded world pharmaceutical market reports have been redesigned to provide enhanced strategic intelligence in a user-friendly format. Each report provides in-depth information, setting the pharmaceutical market in context. The reports provide:
Five-year projections for economic, demographic, health expenditure, health workforce and pharmaceutical market indicators.
Specialised intelligence on OTCs, generics, biologics and biosimilars.
Exclusive economic and demographic data from the Economist Intelligence Unit (EIU) for each market in the series.
A separate statistical health file, comprising health expenditure, health infrastructure, health services and health personnel.
The reports are updated quarterly, providing you with the latest information for a full year. In addition, the service will keep you up to date with market and industry news on a regular basis.
Executive Summary
THE PHARMACEUTICAL MARKET: SLOVENIA - REVIEW
In per capita terms, Slovenia is the richest country in Central & Eastern Europe (CEE), with spending per head at least double that found elsewhere in the former Communist countries of the region. Although the economy contracted in 2009, for the first time in 16 years, economic growth returned in 2010 and the economy is set to increase between 2012 and 2016. Over two-thirds of funding is channelled through the compulsory health insurance system.
Slovenian pharmaceutical production is dominated by two companies, Krka and Lek. Both Krka and Lek play a major role in the Slovenian market and the overall Eastern European market. On 27th October 2011, Krka announced that a new plant for manufacturing solid dosage forms (OTO) had been opened, increasing Krka's production capabilities. The investment into a new production plant was valued at 91.0 million euros (US$122.7 million), and will increase production capacity to 2.5 billion tablets, film-coated tablets and capsules per year.
In February 2010, Lek opened a 430m² modified protein manufacturing facility, which will be used to produce epoetin alfa drug substance for the biosimilars marketed by Lek’s parent company, Sandoz. Epoetin alfa was among the first biosimilars to be marketed in the EU. Sandoz invested US$3.8 million in the Menges site, which will become a global supply point for Sandoz’ modified proteins. Lek previously opened a 2,800m2 Biopharmaceuticals Development Centre in October 2007 and Slovenia’s first manufacturing plant for recombinant technologies in February 2004. Krka and Lek are also seeking to expand their presence in the USA and in the emerging EU generics markets. Lek has had better success in Western markets since 2002, due largely to the Novartis buy-out, and now appears to be pulling significantly ahead of its rival.
ENHANCED STRATEGIC INTELLIGENCE
Espicom's highly regarded world pharmaceutical market reports have been redesigned to provide enhanced strategic intelligence in a user-friendly format. Each report provides in-depth information, setting the pharmaceutical market in context. The reports provide:
Five-year projections for economic, demographic, health expenditure, health workforce and pharmaceutical market indicators.
Specialised intelligence on OTCs, generics, biologics and biosimilars.
Exclusive economic and demographic data from the Economist Intelligence Unit (EIU) for each market in the series.
A separate statistical health file, comprising health expenditure, health infrastructure, health services and health personnel.
The reports are updated quarterly, providing you with the latest information for a full year. In addition, the service will keep you up to date with market and industry news on a regular basis.
HEALTHCARE STATISTICS
A comprehensive tabula review, comprising demographics, epidemiology, health expenditure, hospital and primary care infrastructure & services and healthcare personnel, is additionally included.
Related Pages:
Pharmaceutical Market Slovakia
Pharmaceutical Market Ukraine
More Information...
HIGHLY DETAILED REPORT CONTENT
EXECUTIVE SUMMARY
Including Espicom's at a glance strategic analysis and key data projections
MACROENVIRONMENT
Political, economic, legal and demographic analysis
EPIDEMIOLOGY
Disease burden and prevalence
HEALTHCARE
Organisation, expenditure, infrastructure, services and workforce
REGULATORY AFFAIRS
Regulatory developments and marketing registration/authorisation
PRICING & REIMBURSEMENT
DISTRIBUTION CHANNELS
MARKET ANALYSIS
Projections, product development, manufacturing and trade
COMPETITION
Trade associations, trade fairs, company intelligence and competitive strategies
OTC PHARMACEUTICALS
GENERIC PHARMACEUTICALS
BIOLOGICS & BIOSIMILARS
OPPORTUNITIES & CHALLENGES
Espicom's unique strategic analysis
DIRECTORY
METHODOLOGY & SOURCES
HEALTHCARE STATISTICS
A comprehensive tabula review, comprising demographics, epidemiology, health expenditure, hospital and primary care infrastructure & services and healthcare personnel, is additionally included.
EXECUTIVE SUMMARY
Including Espicom's at a glance strategic analysis and key data projections
MACROENVIRONMENT
Political, economic, legal and demographic analysis
EPIDEMIOLOGY
Disease burden and prevalence
HEALTHCARE
Organisation, expenditure, infrastructure, services and workforce
REGULATORY AFFAIRS
Regulatory developments and marketing registration/authorisation
PRICING & REIMBURSEMENT
DISTRIBUTION CHANNELS
MARKET ANALYSIS
Projections, product development, manufacturing and trade
COMPETITION
Trade associations, trade fairs, company intelligence and competitive strategies
OTC PHARMACEUTICALS
GENERIC PHARMACEUTICALS
BIOLOGICS & BIOSIMILARS
OPPORTUNITIES & CHALLENGES
Espicom's unique strategic analysis
DIRECTORY
METHODOLOGY & SOURCES
Customers who bought this item also bought
All rights reserved. © Copyright 2013 Research and Markets WWW5
Terms and Conditions Privacy Policy Publishers Employment Opportunities Site Map Link to us Webmaster Affiliate Network
